■比较比马前列素两种不同制剂的研究,0.03%和0.01%,表现出类似的功效,但在原发性开角型青光眼(POAG)和高眼压(OHT)患者中,比马前列素的不良反应发生率为0.01%。这项研究评估了在真实世界临床环境中诊断范围更广的患者人群中从比马前列素0.01%切换到0.03%的疗效和耐受性。
■单中心回顾性观察性转换研究。
■选定的患者在转换为0.03%比马前列素之前接受0.01%比马前列素的初始局部治疗。眼内压(IOP)从他们的转换前访问收集,转换后的6周和12周。进行配对双样本t检验以比较不同时间点与基线的IOP。确定转换后充血和其他不良事件的恶化。对POAG和OHT进行亚组分析,继发性开角型青光眼(SOAG,包括假性剥脱性和色素性青光眼),正常眼压性青光眼(NTG),闭角型青光眼(ACG)。
■研究人群包括248只眼(143名患者)。从基线到第6周有1.0±3.7mmHg(p<0.001,n=248)的平均IOP显著降低,从基线到第12周有1.6±4.0mmHg(p<0.001,n=142)。POAG和OHT患者的IOP降低具有统计学意义(6周:1.0±3.8mmHg,n=76;12周:1.5±4.1mmHg,n=49),ACG(6周:1.5±4.1mmHg,n=72;12周:2.3±4.5mmHg,n=46),和NTG(6周:0.83±2.5mmHg,n=42;12周:1.12±2.1mmHg,n=25)。患有SOAG的患者在转换后6周或12周时IOP没有显示出统计学上的显着降低。143例患者中有42例(29%)出现不良事件,最常见的是充血(16%)。
■在除SOAG以外的各种类型的青光眼中,从比马前列素0.01%切换到比马前列素0.03%后,可以看到IOP显著降低。切换后可能会出现不容忍,虽然不是在大多数情况下。
UNASSIGNED: Studies comparing the two different formulations of bimatoprost, 0.03% and 0.01%, have shown similar efficacy, but a better adverse effect profile for bimatoprost 0.01% in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT). This study assesses the efficacy and tolerability of switching from bimatoprost 0.01% to 0.03% in a patient population with broader spectrum of diagnoses in a real-world clinical setting.
UNASSIGNED: Single-centre retrospective observational switch study.
UNASSIGNED: Selected patients were on initial topical therapy with bimatoprost 0.01% prior to switching to bimatoprost 0.03%. Intraocular pressure (IOP) was collected from their pre-switch visit, 6- and 12-week after switch. Paired two-sample t-test was performed to compare IOP at different time points versus baseline. Worsening of hyperemia and other adverse events after the switch were identified. Subgroup analysis was performed for POAG and OHT, secondary open-angle glaucoma (SOAG, including pseudoexfoliative and pigmentary glaucoma), normal tension glaucoma (NTG), and angle closure glaucoma (ACG).
UNASSIGNED: The study population consisted of 248 eyes (143 patients). There was a significant mean IOP reduction of 1.0 ± 3.7 mmHg (p < 0.001, n = 248) from baseline to week-6 and 1.6 ± 4.0 mmHg (p < 0.001, n = 142) from baseline to week-12 after switch. The IOP reduction was statistically significant in patients with POAG and OHT (6-week: 1.0 ± 3.8 mmHg, n = 76; 12-week: 1.5 ± 4.1 mmHg, n = 49), ACG (6-week: 1.5 ± 4.1 mmHg, n = 72; 12-week: 2.3 ± 4.5 mmHg, n = 46), and NTG (6-week: 0.83 ± 2.5 mmHg, n = 42; 12-week: 1.12 ± 2.1 mmHg, n = 25). Patients with SOAG did not show statistically significant reduction in IOP at 6- or 12-week after switch. Forty-two (29%) of 143 patients experienced adverse events, with the most common being hyperemia (16%).
UNASSIGNED: Significant reduction in IOP could be seen after switching from bimatoprost 0.01% to bimatoprost 0.03% in various types of glaucoma except SOAG. Intolerance after switch may be experienced, though not in the majority of cases.